NCT04483206: Phase 1: Personalized Autologous Transplant for Multiple Myeloma
Updated: Jan 27
NCT04483206: Phase 1: Personalized Autologous Transplant for Multiple Myeloma
Personalized Autologous Transplant for Multiple Myeloma
This phase I trial studies the best dose and side effects of mephalan in treating patients with multiple myeloma who are undergoing stem cell transplant. Chemotherapy drugs, such as mephalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial uses a new method of dosing that is based on analysis of each individual's blood levels of melphalan after receiving a part of the dose, termed pharmacokinetic analysis. This may help to learn more about how to dose melphalan correctly and which patients are likely to benefit from a personalized dose.
Sponsor:
Emory University
Collaborators:
National Cancer Institute (NCI)
Gateway for Cancer Research
Location
United States, Georgia
ClinicalTrials.gov Identifier: NCT04483206
Official Title: Phase 1 of Exposure Targeted Melphalan Dosing
First Posted: July 23, 2020
Click here for details on ClinicalTrials.gov
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Melphalan
Other: Questionnaire Administration
Locations
United States, Georgia
United States, Illinois
Comentarios